The performance of commercially available serological tests in real patient samples and the correlates of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided by IgG antibodies are still a matter of debate. A new bioRxiv preprint paper cross-examines the performance of several assays and proclaims the plaque reduction neutralization test (PRNT) as a method of choice.
from News Medical Medical Research News Feed https://ift.tt/2Lm9ML6
0 Comments